EyePoint Pharmaceuticals Inc
NASDAQ:EYPT
EyePoint Pharmaceuticals Inc
Selling, General & Administrative
EyePoint Pharmaceuticals Inc
Selling, General & Administrative Peer Comparison
Competitive Selling, General & Administrative Analysis
Latest Figures & CAGR of Competitors
Company | Selling, General & Administrative | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
EyePoint Pharmaceuticals Inc
NASDAQ:EYPT
|
Selling, General & Administrative
-$51.8m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-21%
|
|
Johnson & Johnson
NYSE:JNJ
|
Selling, General & Administrative
-$21.9B
|
CAGR 3-Years
1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
0%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Selling, General & Administrative
-$7.9B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-5%
|
|
Pfizer Inc
NYSE:PFE
|
Selling, General & Administrative
-$14.5B
|
CAGR 3-Years
-76%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
0%
|
|
Merck & Co Inc
NYSE:MRK
|
Selling, General & Administrative
-$10.4B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
1%
|
|
Eli Lilly and Co
NYSE:LLY
|
Selling, General & Administrative
-$7.6B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-1%
|
See Also
What is EyePoint Pharmaceuticals Inc's Selling, General & Administrative?
Selling, General & Administrative
-51.8m
USD
Based on the financial report for Dec 31, 2023, EyePoint Pharmaceuticals Inc's Selling, General & Administrative amounts to -51.8m USD.
What is EyePoint Pharmaceuticals Inc's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 10Y
-21%
Over the last year, the Selling, General & Administrative growth was 14%. The average annual Selling, General & Administrative growth rates for EyePoint Pharmaceuticals Inc have been -4% over the past three years , -16% over the past five years , and -21% over the past ten years .